What it sells
Delivering RNA therapies.
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharma/biotech drug developers (partners).
Workflow: what inputs become what output?
Designs programmable RNA tags (Mergo) with AI that encode delivery to cell types beyond the liver for RNAi therapeutics.
Economics: what it saves and how it charges
UnverifiedPreclinical biotech platform; value presumably via partnerships/licensing and own pipeline.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2018 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.